ORIONS Money Stocks

[BioSpecialist]

SNGX =MC $49 M/COVID 19 Vaccine + 3 Drugs in Phase 3 with data in Q4 this could be the next NVAX guys .MONSTER opportunity here

Soligenix (SNGX)

Market Cap $49 million
Price 1.83


Presentation
http://ir.soligenix.com/download/Soligenix+Corporate+Presentation+06.24.20FINAL.pdf


Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis
https://finance.yahoo.com/news/soligenix-completes-enrollment-pivotal-phase-110000377.html

Final top-line results expected Q4 2020



SNGX: Q&A on COVID-19 Vaccine Candidate CiVax™…
https://finance.yahoo.com/news/sngx-q-covid-19-vaccine-093900828.html

As a reminder, following the positive topline data presented by the company for SGX-301 in CTCL, we continue to anticipate Phase 3 data for SGX-942 in oral mucositis in the fourth quarter of 2020. The company will also be joining the Russell Microcap Index effective June 29th, 2020, which should help to increase visibility within the investment community. Our current valuation is $12 per share.